You are here

Psoriasis Drug Tildrakizumab Scores in Two Pivotal Trials

Monoclonal antibody increases skin clearance

Tildrakizumab (Sun Pharma), an investigational interleukin (IL)-23p19 inhibitor, has achieved its primary endpoint in two pivotal phase 3 studies (reSURFACE 1 and 2) involving patients with moderate-to-severe plaque psoriasis. An average of 63% of patients showed 75% skin clearance (Psoriasis Area Sensitivity Index [PASI] 75) by week 12 after two injections of tildrakizumab 100 mg, and 77% showed PASI 75 after 28 weeks and three injections.

Similarly, an average of 57% and 66% of patients had a Physician’s Global Assessment (PGA) score of “clear” or “minimal” with the 100-mg dose at weeks 12 and 28, respectively. In addition, 64% and 78% of patients treated with a 200-mg dose of tildrakizumab achieved PASI 75 at weeks 12 and 28, respectively, and 59% and 69% had PGA scores of “clear” or “minimal” at those time points.

The data further showed that a higher number of patients receiving tildrakizumab achieved PASI 90 and PASI 100 compared with placebo and etanercept. An average of 37% and 36% of patients treated with tildrakizumab achieved PASI 90 at week 12 with the 100-mg and 200-mg doses, respectively, which increased to 54% and 59% at week 28. Moreover, an average of 13% of those receiving tildrakizumab achieved PASI 100 at week 12 regardless of the dose, with increases to 24% for the 100 mg-dose and to 30% for the 200-mg dose at week 28.

In both trials, the rates of severe infections, malignancies, and extended major cardiovascular events (MACE) were low and similar across treatment groups (1% to 3%).

Tildrakizumab is an investigational humanized, anti–IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23.

Source: Sun Pharma; October 1, 2016.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
Patient Access to Inhaler Use Data Could Improve Asthma Management
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens